This is the authors' abstract. We don't add key points for this paper.
// Claire Henry 1 , Estelle Llamosas 1 , Alexandra Knipprath-Meszaros 2 , Andreas Schoetzau 2 , Ellen Obermann 3 , Maya Fuenfschilling 3 , Rosemarie Caduff 4 , Daniel Fink 5 , Neville Hacker 6 , Robyn Ward 7 , Viola Heinzelmann-Schwarz 2 , Caroline Ford 1 1 Metastasis Research Group, Adult Cancer Program, Lowy Cancer Research Centre and Prince of Wales Clinical School, Faculty of Medicine, University of New South Wales, New South Wales, Australia 2 Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, University of Basel, Basel, Switzerland 3 Department of Pathology, University Hospital Basel, University of Basel, Basel, Switzerland 4 Department of Pathology, University Hospital Zurich, Zurich, Switzerland 5 Department of Gynecology, University Hospital Zurich, Zurich, Switzerland 6 Gynaecological Cancer Centre, Royal Hospital for Women, Sydney, Australia 7 Department of Research, The University of Queensland, Brisbane, Queensland, Australia Correspondence to: Caroline Ford, e-mail: caroline.ford@unsw.edu.au Keywords: ROR2, ROR1, Wnt signalling, epithelial ovarian cancer, metastasis Received: May 21, 2015 Accepted: October 08, 2015 Published: October 20, 2015 ABSTRACT AIM: In recent years, the Wnt signalling pathway has been implicated in epithelial ovarian cancer and its members have potential as diagnostic, prognostic and therapeutic targets. Here we investigated the role of two Wnt receptor tyrosine kinases (RTKs), ROR1 and ROR2, and their putative ligand, Wnt5a, in ovarian cancer. METHODS: Immunohistochemistry for ROR2 was performed in a large patient cohort, including benign controls, borderline tumours and epithelial ovarian cancer. In addition, siRNA was used to silence ROR1, ROR2 and Wnt5a individually, and together, in two ovarian cancer cell lines, and the effects on cell proliferation, adhesion, migration and invasion were measured. RESULTS: ROR2 expression is significantly increased in ovarian cancer patients compared to patients with benign disease. In vitro assays showed that silencing either receptor inhibits ovarian cancer cell migration and invasion, and concurrently silencing both receptors has an even stronger inhibitory effect on proliferation, migration and invasion. CONCLUSIONS: ROR2 expression is increased in epithelial ovarian cancer, and silencing ROR2 and its sister receptor ROR1 has a strong inhibitory effect on the ability of ovarian cancer cells to proliferate, migrate and invade through an extracellular matrix.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Henry et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: